GlassScriptPhysician profile
Stephen J Keiran
NPI 1548264369
$2,985.44
in general payments reported to CMS, 2019-2025
23 companies · $623 in 2025
The $623 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906 · 2020: $489 · 2021: $245 · 2022: $302 · 2023: $223 · 2024: $198 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,043.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $615.36 | 2019-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $471.34 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $277.47 | 2019-2025 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $247.80 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $239.57 | 2019-2025 | Velphoro, Velphoro |
| Novo Nordisk INC | $131.97 | 2025 | Ozempic, Rybelsus |
| Travere Therapeutics, INC. | $130.85 | 2022-2025 | |
| Akebia Therapeutics INC | $118.34 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.01 | 2021 | |
| Alexion Pharmaceuticals, INC. | $91.85 | 2019-2024 | Ultomiris |
| Horizon Therapeutics Plc | $88.00 | 2019-2023 | Procysbi |
| Opko Pharmaceuticals, LLC | $84.54 | 2019-2022 | |
| Glaxosmithkline, LLC. | $68.83 | 2022-2025 | Benlysta, Arexvy |
| Mallinckrodt Hospital Products INC. | $60.49 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $60.28 | 2020-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $51.92 | 2024 | Cardiomems |
| Invivyd INC | $33.12 | 2024 | Pemgarda |
| Daiichi Sankyo INC. | $30.41 | 2019 | |
| Mallinckrodt Enterprises LLC | $24.07 | 2019 | |
| Nxstage Medical, INC. | $19.58 | 2025 | Liberty Select Cycler, Nxstage System One |
| Ardelyx, INC. | $17.37 | 2024 | Ibsrela |
| Genentech USA, INC. | $12.18 | 2019 | |
| Boston Scientific Corporation | $12.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Keiran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.